Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced financial results for the three months ended March 31, 2023.

First Quarter 2023 Summary & Recent Highlights:

  • Company continues to execute against Transformational Plan
    • Total revenue of $20.5 million, down $5.9 million, or 22%, year-over-year
    • Cash system revenue represented approximately 66% of total systems and subscriptions revenue, compared to 53% in the prior year period
    • Operating expenses of $21.9M, including approximately $0.9 million of costs related to restructuring activities, down $3.3M or 13% year-over-year
    • Cash used in operations down 53% year-over-year
    • GAAP net loss attributable to stockholders of $9.7 million, compared to GAAP net loss attributable to stockholders of $8.6 million last year.
    • Adjusted EBITDA loss of $5.7 million, compared to Adjusted EBITDA loss of $5.9 million last year.
  • On February 3, 2023, the Company announced a restructuring plan to reduce the Company’s cost structure by a total of annual pre-tax savings of $13 million to $15 million beginning in 2024.
  • On May 11, 2023, the Company announced that its Board of Directors approved a 1-for-15 reverse stock split of the Company’s issued and outstanding common stock effective 5:00 p.m. Eastern Daylight Time the same day. The Company’s common stock began trading on The Nasdaq Capital Market on a split-adjusted basis at the open of trading on May 12, 2023.
  • On May 15, 2023, the Company announced that it has entered into a stock purchase agreement with funds affiliated with EW Healthcare Partners for a multi-tranche private placement of senior convertible preferred stock for maximum gross proceeds of up to $9,000,000.

Management Commentary:

“Our first quarter revenue results exceeded the high-end of the Company’s expectations,” said Rajiv De Silva, Chief Executive Officer of Venus Concept. “2023 is a year of re-focusing the business and repositioning Venus Concept to enhance the cash flow profile of the business and to accelerate the path to long-term, sustainable, profitability and growth. To that end, we are encouraged by the early progress towards our restructuring activities designed to improve our operations and cost structure, and our continued strategic shift to prioritize cash system sales which together drove a 53% year-over-year reduction in cash used in operations in Q1.”

Mr. De Silva continued: “We were pleased to announce a new equity financing agreement with our largest shareholder EW Healthcare Partners. We appreciate their continued confidence in the Company. We are evaluating a series of incremental initiatives to accelerate our path to cash flow breakeven - without impacting our 2023 objectives. We remain highly focused on maximizing our capital resources as we work to manage our near-to-intermediate-term debt obligations and to further enhance the Company’s foundation for achieving our longer-term goals.”

 

First Quarter of 2023 Revenue by Region and by Product Type:
  Three Months Ended March 31,
  2023   2022
  (dollars in thousands)
Revenues by region:          
United States $ 10,741   $ 13,129
International   9,790     13,277
Total revenue $ 20,531   $ 26,406
  Three Months Ended March 31,
  2023   2022
  (dollars in thousands)
Revenues by product:          
Subscription—Systems $ 5,761   $ 10,423
Products—Systems   11,065     11,875
Products—Other (1)   2,947     3,497
Services   758     611
Total revenue $ 20,531   $ 26,406
  (1) Products-Other include ARTAS procedure kits, Viva tips and other consumables.
First Quarter 2023 Financial Results:                    
  Three Months Ended March 31,                  
  2023     2022     Change  
(in thousands, except percentages) $     % of Total     $     % of Total     $     %  
Revenues:                                              
Subscription—Systems $ 5,761     28.1     $ 10,423       39.5     $ (4,662 )     (44.7 )
Products—Systems   11,065     53.9       11,875       45.0       (810 )     (6.8 )
Products—Other   2,947     14.3       3,497       13.2       (550 )     (15.7 )
Services   758     3.7       611       2.3       147       24.1  
Total $ 20,531     100.0     $ 26,406       100.0     $ (5,875 )     (22.2 )

Total revenue for the first quarter of 2023 decreased $5.9 million, or 22%, to $20.5 million, compared to the first quarter of 2022. The decrease in total revenue, by region, was driven by a 26% decrease year-over-year in international revenue and a 18% decrease year-over-year in United States revenue. The decrease in total revenue, by product category, was driven by a 45% decrease in lease revenue, a 7% decrease in systems revenue and a 16% decrease in products revenue, offset partially by a 24% increase in services revenue. The percentage of total systems revenue derived from the Company’s subscription model was approximately 34% in the first quarter of 2023, compared to 47% in the prior year period.

Gross profit for the first quarter of 2023 decreased $4.1 million, or 23%, to $13.7 million compared to the first quarter of 2022. The change in gross profit was driven primarily by the year-over-year decline in revenue in the United States and International markets driven by the strategic decision to deemphasize subscription sales and the exit from unprofitable direct markets. Gross margin was 66.7% of revenue, compared to 67.3% of revenue for the first quarter of 2022. The marginal decrease was primarily due to a $0.4 million foreign exchange headwind as a result of most currencies depreciating relative to the U.S. dollar. Adjusting for these factors, our gross margins are slightly above the prior year period.

Operating expenses for the first quarter of 2023 decreased $3.3 million, or 13%, to $21.9 million, compared to the first quarter of 2022. The change in total operating expenses was driven by a decrease of $3.1 million, or 28%, in sales and marketing expenses and a decrease of $0.3 million, 3%, in general and administrative expenses. First quarter of 2023 general and administrative expenses include approximately $0.9 million of costs related to restructuring activities designed to improve the Company's operations and cost structure.

Operating loss for the first quarter of 2023 was $8.2 million, compared to operating loss of $7.4 million for the first quarter of 2022.

Net loss attributable to stockholders for the first quarter of 2023 was $9.7 million, or $1.85 per share, compared to net loss of $8.6 million, or $2.02 per share for the first quarter of 2022. Adjusted EBITDA loss for the first quarter of 2023 was $5.7 million, compared to adjusted EBITDA loss of $5.9 million for the first quarter of 2022.

As of March 31, 2023, the Company had cash and cash equivalents of $6.4 million and total debt obligations of approximately $77.8 million, compared to $11.6 million and $77.7 million, respectively, as of December 31, 2022.

Fiscal Year 2023 Revenue Guidance:

The Company continues to expect total revenue for the twelve months ending December 31, 2023 in the range of $90.0 million to $95.0 million, representing a decrease in the range of approximately 9.5% to 4.5%, year-over-year, compared to total revenue of $99.5 million for the twelve months ended December 31, 2022.

Conference Call Details:

Management will host a conference call at 8:00 a.m. Eastern Time on May 15, 2023, to discuss the results of the first quarter of fiscal year 2023 with a question-and-answer session. Those who would like to participate may dial 877-407-2991 (201-389-0925 for international callers) and provide access code 13737854. A live webcast of the call will also be provided on the investor relations section of the Company's website at ir.venusconcept.com.

For those unable to participate, a replay of the call will be available for two weeks at 877-660-6853 (201-612-7415 for international callers); access code 13737854. The webcast will be archived at ir.venusconcept.com.

About Venus Concept

Venus Concept is an innovative global medical aesthetic technology leader with a broad product portfolio of minimally invasive and non-invasive medical aesthetic and hair restoration technologies and reach in over 60 countries and 14 direct markets. Venus Concept’s product portfolio consists of aesthetic device platforms, including Venus Versa, Venus Legacy, Venus Velocity, Venus Fiore, Venus Viva, Venus Glow, Venus Bliss, Venus BlissMAX, Venus Epileve, Venus Viva MD and AI.ME. Venus Concept’s hair restoration systems include NeoGraft® and the ARTAS iX® Robotic Hair Restoration system. Venus Concept has been backed by leading healthcare industry growth equity investors including EW Healthcare Partners (formerly Essex Woodlands), HealthQuest Capital, Longitude Capital Management, Aperture Venture Partners, and Masters Special Situations.

Cautionary Statement Regarding Forward-Looking Statements

This communication contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Any statements contained herein that are not of historical facts may be deemed to be forward-looking statements. In some cases, you can identify these statements by words such as such as “anticipates,” “believes,” “plans,” “expects,” “projects,” “future,” “intends,” “may,” “should,” “could,” “estimates,” “predicts,” “potential,” “continue,” “guidance,” and other similar expressions that are predictions of or indicate future events and future trends. These forward-looking statements include, but are not limited to, statements about our financial performance and metrics; the growth in demand for our systems and other products and sustainability thereof; and the efficacy of the restructuring plan, workforce reduction and management transition. These forward-looking statements are based on current expectations, estimates, forecasts, and projections about our business and the industry in which the Company operates and management's beliefs and assumptions and are not guarantees of future performance or developments and involve known and unknown risks, uncertainties, and other factors that are in some cases beyond our control. As a result, any or all of our forward-looking statements in this communication may turn out to be inaccurate. Factors that could materially affect our business operations and financial performance and condition include, but are not limited to, general economic conditions and involve risks and uncertainties that may cause results to differ materially from those set forth in the statements and those risks and uncertainties described under Part II Item 1A—“Risk Factors” in our Quarterly Reports on Form 10-Q and Part I Item 1A—“Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022. You are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on the forward-looking statements. The forward-looking statements are based on information available to us as of the date of this communication. Unless required by law, the Company does not intend to publicly update or revise any forward-looking statements to reflect new information or future events or otherwise.

 Venus Concept Inc.Condensed Consolidated Balance Sheets(In thousands of U.S. dollars, except share and per share data)
  March 31,     December 31,  
  2023     2022  
ASSETS              
CURRENT ASSETS:              
Cash and cash equivalents $ 6,414     $ 11,569  
Accounts receivable, net of allowance of $14,207 and $13,619 as of March 31, 2023, and December 31, 2022, respectively   39,147       37,262  
Inventories   22,673       23,906  
Prepaid expenses   1,619       1,688  
Advances to suppliers   5,861       5,881  
Other current assets   2,029       3,702  
Total current assets   77,743       84,008  
LONG-TERM ASSETS:              
Long-term receivables, net   15,325       20,044  
Deferred tax assets   799       947  
Severance pay funds   698       741  
Property and equipment, net   1,743       1,857  
Operating right-of-use assets, net   5,439       5,862  
Intangible assets   11,063       11,919  
Total long-term assets   35,067       41,370  
TOTAL ASSETS $ 112,810     $ 125,378  
LIABILITIES AND STOCKHOLDERS’ EQUITY              
CURRENT LIABILITIES:              
Trade payables $ 7,511     $ 8,033  
Accrued expenses and other current liabilities   14,965       16,667  
Current portion of long-term debt   7,735       7,735  
Income taxes payable   187       117  
Unearned interest income   2,222       2,397  
Warranty accrual   945       1,074  
Deferred revenues   952       1,765  
Operating lease liabilities   1,688       1,807  
Total current liabilities   36,205       39,595  
LONG-TERM LIABILITIES:              
Long-term debt   70,078       70,003  
Income tax payable   379       374  
Accrued severance pay   834       867  
Unearned interest revenue   772       957  
Warranty accrual   391       408  
Operating lease liabilities   3,932       4,221  
Other long-term liabilities   426       215  
Total long-term liabilities   76,812       77,045  
TOTAL LIABILITIES   113,017       116,640  
Commitments and Contingencies (Note 9)              
STOCKHOLDERS’ EQUITY (Note 15):              
Common Stock, $0.0001 par value: 300,000,000 shares authorized as of March 31, 2023 and December 31, 2022; 5,388,074 and 5,141,688 issued and outstanding as of March 31, 2023, and December 31, 2022, respectively   30       29  
Additional paid-in capital   233,394       232,169  
Accumulated deficit   (234,310 )     (224,105 )
TOTAL STOCKHOLDERS’ EQUITY   (886 )     8,093  
Non-controlling interests   679       645  
    (207 )     8,738  
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $ 112,810     $ 125,378  
   
The accompanying notes are an integral part of these consolidated financial statements.  
Venus Concept Inc.Condensed Consolidated Statements of Operations(In thousands of U.S. dollars, except per share data)
  Three Months Ended March 31,  
  2023     2022  
Revenue              
Leases $ 5,761     $ 10,423  
Products and services   14,770       15,983  
    20,531       26,406  
Cost of goods sold              
Leases   1,747       2,700  
Products and services   5,085       5,943  
    6,832       8,643  
Gross profit   13,699       17,763  
Operating expenses:              
Selling and marketing   8,032       11,084  
General and administrative   11,185       11,472  
Research and development   2,637       2,643  
Total operating expenses   21,854       25,199  
Loss from operations   (8,155 )     (7,436 )
Other expenses:              
Foreign exchange loss (gain)   (352 )     5  
Finance expenses   1,508       923  
Loss on disposal of subsidiaries   77       -  
Loss before income taxes   (9,388 )     (8,364 )
Income tax expense   235       272  
Net loss   (9,623 )     (8,636 )
Net loss attributable to stockholders of the Company   (9,657 )     (8,619 )
Net income (loss) attributable to non-controlling interest   34       (17 )
               
Net loss per share:              
Basic $ (1.85 )   $ (2.02 )
Diluted $ (1.85 )   $ (2.02 )
Weighted-average number of shares used in per share calculation:              
Basic   5,218       4,265  
Diluted   5,218       4,265  
Venus Concept Inc.Condensed Consolidated Statements of Cash Flows(in thousands)
  Three Months Ended March 31,  
  2023     2022  
CASH FLOWS FROM OPERATING ACTIVITIES:              
Net loss $ (9,623 )   $ (8,636 )
Adjustments to reconcile net loss to net cash used in operating activities:              
Depreciation and amortization   1,007       1,101  
Stock-based compensation   481       443  
Provision for expected credit losses   618       1,004  
Provision for inventory obsolescence   343       135  
Finance expenses and accretion   74       79  
Deferred tax recovery   149       45  
Loss on disposal of property and equipment   34       -  
Changes in operating assets and liabilities:              
Accounts receivable short-term and long-term   1,654       (3,199 )
Inventories   891       (911 )
Prepaid expenses   69       291  
Advances to suppliers   20       (4,226 )
Other current assets   1,673       (381 )
Operating right-of-use assets, net   423       (6,299 )
Other long-term assets   (45 )     -  
Trade payables   (522 )     2,731  
Accrued expenses and other current liabilities   (2,570 )     (1,128 )
Current operating lease liabilities   (119 )     1,664  
Severance pay funds   43       (67 )
Unearned interest income   (360 )     70  
Long-term operating lease liabilities   (289 )     4,635  
Other long-term liabilities   161       225  
Net cash used in operating activities   (5,888 )     (12,424 )
CASH FLOWS FROM INVESTING ACTIVITIES:              
Purchases of property and equipment   (70 )     (157 )
Net cash used in investing activities   (70 )     (157 )
CASH FLOWS FROM FINANCING ACTIVITIES:              
Proceeds from exercise of options         23  
Proceeds from issuance of common stock   803        
Repayment of government assistance loans         (407 )
Net cash (used in) provided by financing activities   803       (384 )
NET DECREASE IN CASH AND CASH EQUIVALENTS AND RESTRICTED CASH   (5,155 )     (12,965 )
CASH AND CASH EQUIVALENTS AND RESTRICTED CASH — Beginning of period   11,569       30,876  
CASH AND CASH EQUIVALENTS AND RESTRICTED CASH — End of period $ 6,414     $ 17,911  
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:              
Cash paid for income taxes $ 12     $ 99  
Cash paid for interest $ 1,433     $ 844  
FINANCING INFORMATION:              
Common stock issuance costs          

Use of Non-GAAP Financial Measures

Adjusted EBITDA is a non-GAAP measure defined as net income (loss) before foreign exchange loss (gain), financial expenses, income tax expense (benefit), depreciation and amortization, stock-based compensation and non-recurring items for a given period. Adjusted EBITDA is not a measure of our financial performance under U.S. GAAP and should not be considered an alternative to net income or any other performance measures derived in accordance with U.S. GAAP. Accordingly, you should consider Adjusted EBITDA along with other financial performance measures, including net income, and our financial results presented in accordance with U.S. GAAP. Other companies, including companies in our industry, may calculate Adjusted EBITDA differently or not at all, which reduces its usefulness as a comparative measure. We understand that although Adjusted EBITDA is frequently used by securities analysts, lenders and others in their evaluation of companies, Adjusted EBITDA has limitations as an analytical tool, and you should not consider it in isolation, or as a substitute for analysis of our results as reported under U.S. GAAP. Some of these limitations are: Adjusted EBITDA does not reflect our cash expenditures or future requirements for capital expenditures or contractual commitments; Adjusted EBITDA does not reflect changes in, or cash requirements for, our working capital needs; and although depreciation and amortization are non-cash charges, the assets being depreciated will often have to be replaced in the future, and Adjusted EBITDA does not reflect any cash requirements for such replacements.

We believe that Adjusted EBITDA is a useful measure for analyzing the performance of our core business because it facilitates operating performance comparisons from period to period and company to company by backing out potential differences caused by changes in foreign exchange rates that impact financial assets and liabilities denominated in currencies other than the U.S. dollar, tax positions (such as the impact on periods or companies of changes in effective tax rates), the age and book depreciation of fixed assets (affecting relative depreciation expense), amortization of intangible assets, stock-based compensation expense (because it is a non-cash expense) and non-recurring items as explained below.The following reconciliation of net (loss) income to Adjusted EBITDA for the periods presented:

Venus Concept Inc.Reconciliation of Net loss to Non-GAAP Adjusted EBITDA  
  Three Months Ended March 31,  
  2023     2022  
Reconciliation of net loss to adjusted EBITDA (in thousands)  
Net loss $ (9,623 )   $ (8,636 )
Foreign exchange loss (gain)   (352 )     5  
Loss on disposal of subsidiaries   77        
Finance expenses   1,508       923  
Income tax expense   235       272  
Depreciation and amortization   1,022       1,101  
Stock-based compensation expense   481       443  
Other adjustments (1)   917        
Adjusted EBITDA $ (5,735 )   $ (5,892 )

(1) For the three months ended March 31, 2023, the other adjustments are represented by restructuring activities designed to improve the Company's operations and cost structure. 

 

Investor Relations Contact:

ICR Westwicke on behalf of Venus Concept:

Mike Piccinino, CFA

VenusConceptIR@westwicke.com
Venus Concept (NASDAQ:VERO)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Venus Concept Charts.
Venus Concept (NASDAQ:VERO)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Venus Concept Charts.